Skip to main content

Psoriatic Arthritis

Rheumatology Consultant
He talks about the challenges of treating progressive psoriatic arthritis, why certain patients progress to more severe disease, and how to change medication when needed.
Rheumatology Consultant
The leading cause of death in patients with psoriatic arthritis is cardiovascular disease, which is often linked in part to depression, anxiety, and other mental health issues. How do you assess your patients for depression and anxiety?
The Dermatologist
The FDA approved guselkumab, a selective IL-23 inhibitor, for the treatment of adult patients with active psoriatic arthritis.
Rheumatology Consultant
Patients with psoriatic arthritis have longer duration of disease and take higher doses of glucocorticoids than patients with rheumatic arthritis. What does new research show about the relative bone mineral densities of patients with RA vs PsA?
Findings from an interim analysis showed patients with psoriatic arthritis treated with tofacitinib for over 2 years maintained efficacy with a similar safety profile to phase 3 studies.
Back to Top